# US 2010/0303859 A1 · Vectors and method for genetic immunization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303859 A1
- Document ID: US20100303859A1
- Status: Published application
- Kind: A1
- Application number: 12/601,970
- Filed: 2008-05-22
- Published: 2010-12-02
- Earliest claimed: 2007-05-29
- Assignees: Nature Technology Corporation
- Inventors: James A. Williams
- Web page: https://patentgrep.com/patent/US20100303859A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C07K 14/005: from viruses
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12N 15/85: for animal cells
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C12N 2310/11: Antisense
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/532: Closed or circular
- C12N 2320/30: Special therapeutic applications
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2800/106: for vertebrates
- C12N 2800/107: for mammalian
- C12N 2830/00: Vector systems having a special element relevant for transcription
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method for modifying the response of an individual or eukaryotic cell to at least one vector comprising the steps of:
a. obtaining at least one vector containing at least one RNA element comprising a VARNA, and at least one additional immunostimulatory RNA element, and
b. optionally cloning at least one gene encoding a protein or peptide into said vector(s), and
c. delivering said vector(s) to said individual or said eukaryotic cell, and
d. evaluating immune response or type 1 interferon production after said delivery of said vector(s),
whereby said combination of VARNA and at least one additional immunostimulatory RNA element improves immune response and/or improves type 1 interferon production by said individual or said eukaryotic cell without reducing antigen expression.

### Claim 17 (depends on 16)

The method of claim 16, wherein said vector is chosen from the group consisting of: non-viral vector, viral vector, alphavirus vector, poxvirus vector, lentivirus vector, retrovirus vector, adenovirus vector, adenovirus related virus vector, plasmid vector, midge vector, transcriptionally active PCR fragment vector, minicircle vector, bacteriophage vector.

### Claim 18 (depends on 16)

The method of claim 16, wherein said VARNA comprises VARNAI or VARNAII from any adenoviral serotype, or hybrids thereof, and said VARNA derivative is chosen from the group consisting of: VARNA-short hairpin RNA fusion constructs; VARNA internal deletions or substitutions; VARNA point mutations with at least 90% sequence identity to VARNA; and VARNAI incorporating the pm91 mutation.

### Claim 19 (depends on 16)

The method of claim 16, wherein said VARNA is combined with at least one additional immunostimulatory RNA element chosen from the group consisting of: tRNA expressed single stranded RNA elements, RNA Polymerase III promoter expressed single stranded RNA elements, convergent tRNA and RNA Polymerase III promoter expressed double stranded RNA elements, and RNA Polymerase III promoter expressed hairpin RNA elements.

### Claim 20 (depends on 16)

The method of claim 16, wherein said individual is a mammal, bird or fish.

### Claim 21

A method for modifying the response of a individual or eukaryotic cell to a vector comprising the steps of:
a. obtaining a vector comprising at least one immunostimulatory RNA element that comprises a tRNA, optionally a linker, an RNA to be expressed, and an RNA polymerase III promoter arranged in opposite orientation to said tRNA, such that transcription of said RNA is convergent, and
b. optionally cloning at least one gene that encode a protein or peptide into said vector, and
c. delivering said vector to a eukaryotic cell, and
d. evaluating immune response or type 1 interferon production after said delivery of said vector,
whereby said RNA element improves immune response and/or improves type 1 interferon production by said individual or said eukaryotic cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein said vector is chosen from the group consisting of: non-viral vector, viral vector, alphavirus vector, poxvirus vector, lentivirus vector, retrovirus vector, adenovirus vector, adenovirus related virus vector, plasmid vector, midge vector, transcriptionally active PCR fragment vector, minicircle vector, bacteriophage vector.

### Claim 23

A composition of matter comprising two immunostimulatory RNA elements, further comprising:
a. a VARNA RNA element or a VARNA derivative RNA element, and
b. a second RNA element,
whereby the combination of said VARNA RNA element with said second RNA element improves type 1 interferon production and/or immune response without reducing antigen expression.

### Claim 24 (depends on 23)

The composition of claim 23, wherein said VARNA comprises VARNAI or VARNAII from any adenoviral serotype, or hybrids thereof, and said VARNA derivative is chosen from the group consisting of: VARNA-short hairpin RNA fusion constructs; VARNA internal deletions or substitutions; VARNA point mutations with at least 90% sequence identity to VARNA; and VARNAI incorporating the pm91 mutation.

### Claim 25 (depends on 23)

The composition of claim 23, wherein said second RNA element is chosen from the group consisting of: tRNA expressed single stranded RNA elements; RNA Polymerase III promoter expressed single stranded RNA elements; convergent tRNA and RNA Polymerase III promoter-expressed double stranded RNA elements; and RNA Polymerase III promoter expressed hairpin RNA elements.

### Claim 26

A method for modifying the response of an individual to a vector comprising the steps of:
a. cloning at least one gene that encodes a protein or peptide into a vector that contains a mitochondrial R region, and
b. optionally cloning at least one immunostimulatory RNA element into said vector, and
c. delivering said vector to a eukaryotic cell, and
d. evaluating immune response after said delivery of said vector,
whereby said mitochondrial R region improves immune response to said protein or said peptide.

### Claim 27

A method for selection and propagation of antibiotic marker-free covalently closed, super-coiled DNA replicon, such as a plasmid, a cosmid, or a bacterial artificial chromosome, in E. coli, comprising the steps of:
a. cloning a RNA-OUT antisense RNA into said DNA replicon, and
b. transforming said RNA-OUT antisense RNA containing DNA replicon into bacterial cells that express a selectable chromosomal gene under the control of a RNA-IN sense RNA, and
c. isolating transformed bacterial cells under selection, and
d. propagating said transformed bacterial cells under conditions that accumulate said DNA replicon,
whereby said method replaces selection by an antibiotic marker in said DNA replicon, for said DNA replicon isolation or propagation.

### Claim 28 (depends on 27)

The method of claim 27 wherein said chromosomal gene under control of the RNA-IN sense sequence encodes a levansucrase, and said transformed bacterial cells are isolated by growth in the presence of sucrose.

### Claim 29 (depends on 27)

The method of claim 27 wherein said antibiotic marker-free DNA replicon is used for production of biological molecules chosen from the group consisting of: plasmids, proteins, RNAs, nucleotides, biosynthetic pathway products, or biosynthetic pathway intermediates, or combinations thereof.

### Claim 30

A composition of matter for a vector comprising:
a. an RNA-OUT antisense RNA with at least 90% sequence identity to the sequence set forth as SEQ ID NO: 15, operably linked to,
b. a plasmid, cosmid, or bacterial artificial chromosome DNA replicon, whereby said RNA-out antisense RNA is used to select and propagate said DNA replicon.

### Claim 31

A composition of matter for a vector comprising:
a. a promoter with at least 95% sequence identity to the sequence set forth as SEQ ID NO: 6 operable linked to,
b. a gene of interest,
whereby said promoter is used to express said gene of interest.

### Claim 32

A composition of matter for a vector comprising:
a. a promoter with at least 95% sequence identity to the sequence set forth as SEQ ID NO: 6 operable linked to,
b. a gene of interest, and
c. a VARNA
d. optionally at least one additional immunostimulatory RNA element
whereby said promoter is used to express said gene of interest and said VARNA is used to increase expression of said gene of interest.
